Related Experiment Video

Updated: Jun 1, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Pediatric cardiovascular drug development and research: integration of modeling and simulation as one future

Stephanie Läer1

  • 1Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany. stephanie.laeer@uni-duesseldorf.de

Journal of Cardiovascular Pharmacology
|June 10, 2011
PubMed

Insights

Pediatric drug development regulations have improved medicine safety and efficacy for children. Innovative clinical trial designs and advanced technologies like in silico modeling will further enhance pediatric drug outcomes.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Regulatory Science

Background:

  • Legislation in the US (since 1997) and EU (since 2007) integrated pediatric needs into drug development.
  • This has led to 394 pediatric labels, safer medicines, and improved dosing practices, benefiting children's health.
  • While progress is evident, challenges like nonefficacy and safety issues persist in pediatric populations.

Purpose of the Study:

  • To evaluate the impact of integrating pediatric needs into drug development.
  • To highlight advancements in clinical trial design and pediatric medicine.
  • To discuss challenges and future directions in pediatric drug research.

Main Methods:

  • Analysis of regulatory changes and their impact on pediatric drug labeling.
  • Review of data generated from pediatric clinical trials.
  • Exploration of advanced technologies for pediatric trial design.

Main Results:

  • Significant improvements in pediatric drug safety and efficacy have been achieved.
  • Enhanced understanding of pediatric drug use, potentially reducing medication errors and hospital stays.
  • Identification of heterogeneity in pediatric populations as a key challenge.

Conclusions:

  • Pediatric drug development regulations have positively impacted children's health and medicine.
  • Future research should focus on addressing heterogeneity and leveraging technologies like in silico modeling.
  • Continued innovation in clinical trial design is crucial for optimizing pediatric drug outcomes.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...